The company's Check4 electrochemical detection platform can detect nucleic acid targets from blood or saliva samples in less than five minutes.

The analyzer integrates clinical chemistries, immunoassays, and hematology assays into a single plug-and-play instrument.

The PCR-based point-of-care test runs on the Cobas Liat platform and returns results for three Bordetella species in 15 minutes.

The blood-based test is intended to aid in the decision for prostate biopsy for men older than 50 with elevated PSA levels.

Of the 30 companies in the index, 25 saw their share prices increase and four saw their stock prices decline, while one company was flat month over month.

Last week, readers were most interested in a story about FDA's plan to reclassify some tests that now require PMAs to require only 510(k) clearance.